Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Fibroblast Growth Factor Receptor”

72 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 72 results

Not applicableLooking for participantsNCT06410976
What this trial is testing

Prospective Clinical Assessment Study in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 150
Testing effectiveness (Phase 2)Ended earlyNCT03822117
What this trial is testing

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Who this might be right for
Solid Tumor Malignancy
Incyte Corporation 111
Testing effectiveness (Phase 2)Study completedNCT05529667
What this trial is testing

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Who this might be right for
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
Yonsei University 15
Large-scale testing (Phase 3)Active Not RecruitingNCT05052801
What this trial is testing

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Amgen 547
Testing effectiveness (Phase 2)UnknownNCT05775874
What this trial is testing

Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Who this might be right for
Urothelial Carcinoma
Abbisko Therapeutics Co, Ltd 80
Early research (Phase 1)Study completedNCT02038673
What this trial is testing

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Who this might be right for
Solid Tumors
Astellas Pharma Inc 86
Testing effectiveness (Phase 2)Ended earlyNCT03827850
What this trial is testing

FGFR Inhibitor in FGFR Dysregulated Cancer

Who this might be right for
Lung CancerNSCLCPulmonary Neoplasm+2 more
Lung Cancer Group Cologne 22
Not applicableUnknownNCT03324022
What this trial is testing

Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease

Who this might be right for
Graves Ophthalmopathy
National Taiwan University Hospital 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT05544552
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid Tumor+11 more
Tyra Biosciences, Inc 310
Large-scale testing (Phase 3)Ended earlyNCT04197986
What this trial is testing

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Who this might be right for
Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
QED Therapeutics, a BridgeBio company 39
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Testing effectiveness (Phase 2)Study completedNCT02924376
What this trial is testing

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Who this might be right for
Cholangiocarcinoma
Incyte Corporation 147
Testing effectiveness (Phase 2)Study completedNCT02699606
What this trial is testing

Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Who this might be right for
Neoplasm
Janssen Research & Development, LLC 35
Not applicableStudy completedNCT03816605
What this trial is testing

FGF19 and the Expression of IRS-1 and GLUT-1 in Gestational Diabetes Mellitus

Who this might be right for
Gestational Diabetes Mellitus
First Affiliated Hospital, Sun Yat-Sen University 36
Not applicableStudy completedNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Not applicableApproved For MarketingNCT03825484
What this trial is testing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Who this might be right for
Advanced Cancers and FGFR Genetic Alterations
Janssen Scientific Affairs, LLC
Early research (Phase 1)WithdrawnNCT04972253
What this trial is testing

Phase I BLASST-3 Trial

Who this might be right for
Bladder Transitional Cell CarcinomaBladder CancerFibroblast Growth Factor Receptor
Guru P. Sonpavde
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Testing effectiveness (Phase 2)Study completedNCT04045613
What this trial is testing

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
Basilea Pharmaceutica 95
Testing effectiveness (Phase 2)Study completedNCT01719549
What this trial is testing

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Who this might be right for
Gastric Cancer
Asan Medical Center 19
Load More Results